DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the GLAND PHARMA LIMITED (GLAND) share price today?

GLAND PHARMA LIMITED (GLAND) is trading at ₹2,449 on the NSE, down 3.18% on the day. Source: DocStoX.

What is the PE ratio of GLAND PHARMA LIMITED?

GLAND PHARMA LIMITED has a price-to-earnings (PE) ratio of 39.3 in the Healthcare sector.

What is the market capitalisation of GLAND PHARMA LIMITED?

GLAND PHARMA LIMITED has a market capitalisation of approximately ₹40,361 crore.

GLAND PHARMA LIMITED

GLAND·NSE·Healthcare

₹2,449.00▼ -80.40 (-3.18%)

Healthcare · Pharmaceuticals

Revenue compounding 21% a year

NIFTY 500NIFTY SMALLCAP 250NIFTY PHARMA

Day₹2435.00

₹2539.00

52W₹1574

₹257488%

Open

₹2529.40

High

₹2539.00

Low

₹2435.00

Prev Close

₹2529.40

Volume

3.27L

VWAP

₹2459.94

Snapshot

Key fundamentals

Market Cap

₹40,361 Cr

P/E Ratio

39.28Expensive

P/B Ratio

3.89

EPS

₹62.35

Book Value

₹629.00

ROE

10.70%Average

ROCE

15.00%Decent

Dividend Yield

0.78%

Debt / Equity

0.03Low

Face Value

₹1.00

52W High

₹2573.50

52W Low

₹1573.60

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

Narrow moatHigh uncertainty

Fair value estimate

₹681

▼ 72.2%downside

Trading at ₹2,449 — 72% above our estimate

BearFair valueBull

₹579₹681₹939

/100

Business quality — Solid

Growth 61Profitability 53Efficiency 18Valuation 63

Plain English

Our view

Revenue compounding 21% a year
Virtually debt-free balance sheet
Fundamental red flags (Piotroski 2/9)

Strengths

Virtually debt-free balance sheet
Revenue compounding 21% over 3 years
Promoters hold a controlling stake

Risks

Fundamental red flags (Piotroski 2/9)

How we got there

Fair value methods

Residual income

11% ROE fading to 12% over ~10 yrs, on ₹629 book

₹609

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹939

Analyst target

No analyst coverage

—

Blended fair value₹681

What the numbers say

Investment thesis

Bull case

Virtually debt-free balance sheet
Revenue compounding 21% over 3 years
Promoters hold a controlling stake

Bear case

Fundamental red flags (Piotroski 2/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

39.3Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

10.7%Average

Above 15% is considered healthy for Indian equities

ROCE

15.0%Decent

Above 18% means capital is working hard

Debt/Eq

0.03Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹40,361 Cr

P/B

3.89

EPS

₹62.35

Div Yield

0.78%

What changed

Recent changes

Foreign investors-0.3% stake last quarter
Domestic institutions+0.4% stake last quarter

What matters

News impact

Overview

Valuation

Expensive

P/E 39.3×

Growth

Strong

+21% rev CAGR

Profitability

Modest

10.7% ROE

Financial health

Rock solid

D/E 0.03

Momentum

N/A

No technicals

Today

Trading activity

Delivery %52.4%

Turnover₹8043.03L Cr

Trades31,063

VWAP₹2459.94

Face value₹1.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+21.1%

+13.2%

10Y

+16.9%

Profit

+9.6%

+0.6%

10Y

+12.6%

EPS

+9.6%

+0.5%

10Y

-11.1%

Profile

Pros

Company is almost debt free.
Company has been maintaining a healthy dividend payout of 39.1%

Watch-outs

Cons

Stock is trading at 3.94 times its book value
Company has a low return on equity of 9.30% over last 3 years.
Promoter holding has decreased over last 3 years: -6.03%

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Foreign investors sold 0.29 pts; domestic institutions added 0.37 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

52%

Promoter

Promoters

51.8%0.00

Public

7.5%-0.10

FII / FPI

7.3%-0.29

DII

33.4%+0.37

Total shareholders

91,500-3,078 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter51.83%

FII7.29%

DII33.36%

Public7.52%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions